Beam Therapeutics Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Beam Therapeutics Inc. (BEAM) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$1.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-04
- Beam Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$1.12M.
- Beam Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$2.18M.
- Beam Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $780.00K, a 72.81% decline year-over-year.
- Beam Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was -$150.00K.
- Beam Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $432.00K, a 476.00% increase from fiscal 2024.
- Beam Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $75.00K, a 97.53% decline from fiscal 2023.
- Beam Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $3.03M.
- Beam Therapeutics Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$2.38M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.12M 10-Q · filed 2026-08-04 | -$3.30M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2026-03-31 | -$2.18M 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $432.00K 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $780.00K 10-Q · filed 2025-11-04 | $630.00K derived: sum of 2 quarters · filed 2026-08-04 | $111.00K derived: sum of 3 quarters · filed 2026-08-04 | |
| 2025-06-30 | -$150.00K 10-Q · filed 2026-08-04 | -$669.00K derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2025-03-31 | -$519.00K 10-Q · filed 2026-08-04 | |||
| 2024-12-31 | $75.00K 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $2.87M 10-Q · filed 2025-11-04 | $2.68M derived: sum of 2 quarters · filed 2025-11-04 | $1.16M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | -$189.00K 10-Q · filed 2025-11-04 | -$1.71M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | -$1.52M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $3.03M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | -$9.00K 10-Q · filed 2024-11-05 | -$1.26M derived: sum of 2 quarters · filed 2024-11-05 | $406.00K derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | -$1.25M 10-Q · filed 2024-11-05 | $415.00K derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $1.67M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | -$2.38M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | -$484.00K 10-Q · filed 2023-11-08 | -$1.97M derived: sum of 2 quarters · filed 2023-11-08 | -$4.62M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | -$1.48M 10-Q · filed 2023-11-08 | -$4.14M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | -$2.66M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | -$41.00K 10-K · filed 2024-02-27 | |||
| 2021-09-30 | -$12.00K 10-Q · filed 2022-11-07 | $43.00K derived: sum of 2 quarters · filed 2022-11-07 | $28.00K derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $55.00K 10-Q · filed 2022-11-07 | $40.00K derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | -$15.00K 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | -$25.00K 10-K · filed 2023-02-28 | |||
| 2020-09-30 | -$132.00K 10-Q · filed 2021-11-08 | $385.00K derived: sum of 2 quarters · filed 2021-11-08 | $25.00K derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $517.00K 10-Q · filed 2021-11-08 | $157.00K derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | -$360.00K 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $16.00K 10-K · filed 2022-02-28 | |||
| 2019-09-30 | -$35.00K 10-Q · filed 2020-11-10 | $48.00K derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-06-30 | $83.00K 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |